Atrial Fibrillation

Cardiovascular·MeSH: Atrial Fibrillation

Prevalence

1200.0 / 100K

Incidence

100.0 / 100K/yr

34 drugs in development·18 companies·25 clinical trials

Drug Pipeline by Phase

Approved(5)

Phase 3(9)

Drug	Company
abelacimab	Dianthus Therapeutics, Inc. /DE/ (DNTH)
Androgen-deprivation Therapy	Crinetics Pharmaceuticals, Inc. (CRNX)
Consolidation Therapy	Crinetics Pharmaceuticals, Inc. (CRNX)
Maintenance Therapy	Crinetics Pharmaceuticals, Inc. (CRNX)
milvexian	GH Research PLC (GHRS)
nPulse Cardiac Catheter System	Pulse Biosciences Inc Common Stock (DE) (PLSE)
nPulse Cardiac Surgical Clamp (nsPFA Cardiac Surgery System)	Pulse Biosciences Inc Common Stock (DE) (PLSE)
Re-induction Therapy	Crinetics Pharmaceuticals, Inc. (CRNX)
Rescue medications for sacituzumab tirumotecan	Merus N.V. (MRUS)

Phase 2(4)

Drug	Company
pkn605	Novartis AG (NVS)
pkn605	NOVARTIS AG (NVSEF)
regn7508	REGENERON PHARMACEUTICALS, INC. (REGN)
regn9933	REGENERON PHARMACEUTICALS, INC. (REGN)

Phase 1(1)

Drug	Company
Rescue Medications	Merus N.V. (MRUS)

Preclinical(1)

Drug	Company
pulsed field cryoablation	Adagio Medical Holdings Inc (ADGM)

Unknown(5)

Drug	Company
CellFX nsPFA 360° Cardiac Catheter	Pulse Biosciences Inc Common Stock (DE) (PLSE)
CellFX nsPFA Cardiac Clamp	Pulse Biosciences Inc Common Stock (DE) (PLSE)
gencaro	Oruka Therapeutics, Inc. (ORKA)
non-vitamin k oral anticoagulant	BRAIN SCIENTIFIC INC. (BRSF)
nspfa cardiac surgical system	Pulse Biosciences Inc Common Stock (DE) (PLSE)

N/A(1)

Drug	Company
Optimized Medical Therapy for Atrial Fibrillation	Crinetics Pharmaceuticals, Inc. (CRNX)

Phase 2/Phase 3(1)

Drug	Company
tecarfarin	Cadrenal Therapeutics, Inc. (CVKD)

Phase 4(7)

Drug	Company
flecainide	CYTOKINETICS INC (CYTK)
Nicotine Replacement Therapy	Crinetics Pharmaceuticals, Inc. (CRNX)
pantoprazole	GH Research PLC (GHRS)
rebamipide	GH Research PLC (GHRS)
Sacubitril-valsartan	ENANTA PHARMACEUTICALS INC (ENTA)
Sotalol or Amiodarone	CYTOKINETICS INC (CYTK)
Valsartan	ENANTA PHARMACEUTICALS INC (ENTA)

BioSniper tracks 34 drugs in development for Atrial Fibrillation across 18 companies.

There are 25 clinical trials targeting Atrial Fibrillation tracked by BioSniper.

The estimated prevalence of Atrial Fibrillation is approximately 1200.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.